At Embedded World 2026 (Embedded Electronics and Industrial Computing Applications Exhibition) held in Nuremberg, Germany this year, Intel officially announced the Core Series 2 processor, featuring up to 12 P-core performance cores and targeting demanding industrial and medical applications. This processor serves as an industrial-grade computing platform built for mission-critical edge applications. Simultaneously, to accelerate AI innovation in the medical and life sciences fields, Intel also released its sixth Edge AI Suite for Health & Life Sciences, providing proven reference workflows to help medical device manufacturers quickly build AI-enabled patient monitoring solutions.
Core Series 2 processors, designed for demanding industrial and medical applications: directly addressing the industry's pain points of "immediacy and determinism".
In modern industrial automation, processors often need to handle multiple extreme workloads simultaneously—from safety-critical control systems to real-time, massive data processing. Traditional architectures often force manufacturers to compromise between computing power and real-time reliability, ultimately resorting to complex and expensive multiprocessor architectures to solve the problem.
The all-new Core Series 2 processors, designed for demanding industrial and medical applications, are created to break this deadlock. Featuring powerful P-core performance cores, Intel emphasizes that the new processors can handle high-load computing tasks while maintaining precise timing and deterministic performance.
To demonstrate its capabilities in harsh industrial environments, Intel directly targeted its competitors. According to official Intel data, compared to the AMD Ryzen 7 9700X, the Core Series 2 processors show significant improvements in all key industrial metrics:
• Maximum PCIe latency:The reduction was as much as 4.4 times.
• Deterministic response time:Up to 2.5 times higher.
• Certainty efficacy:Up to 3.8 times higher.
• Multi-threaded performance:Up to 1.5 times higher.
Medical Edge AI Kit: Accelerating the Smartening of Patient Monitoring Devices
In addition to showcasing its hardware capabilities, Intel also previewed its next-generation Edge AI software suite, designed specifically for the "Health & Life Sciences" sector.
Faced with the increasing number of patients and the shortage of medical staff in global healthcare systems, traditional "isolated" medical monitoring equipment is no longer sufficient, and the market is rapidly shifting towards a connected ecosystem with AI insights. This software suite launched by Intel directly demonstrates how to simultaneously execute multimodal AI workloads "locally" on Intel processors, including:
• AI-based ECG arrhythmia detection
• Remote photoplethysmography (rPPG):Physiological data such as heart rate can be measured non-contactly through a camera lens.
• Anonymous 3D visual tracking:Monitor patient activity (such as fall detection) while protecting patient privacy.
This tool not only provides benchmarking, but also allows OEMs, ODMs, and ISVs (Independent Software Vendors) to use "real-world representative scenarios" rather than synthetic data to evaluate platform performance, significantly shortening the development cycle of medical AI devices.
Dan Rodriguez, Corporate Vice President and General Manager of Intel's Edge Computing Group, stated, "Edge computing remains one of Intel's fastest-growing business units. This aligns with the earlier announcement at CES 2026..."Core Ultra Series 3"And with the ever-expanding Edge AI suite, we are continuously providing a comprehensive platform that meets the diverse needs of our edge customers."
Regarding availability, edge systems equipped with Intel Core Ultra Series 3 and Core Series 2 are now officially available; while preview versions of the Medical and Life Sciences Edge AI Suite are currently available through GitHub and are expected to be fully available in the second quarter of 2026.
